Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer
Kun Fan, Chao Yang, Zhiyao Fan, et al.
Cancer Letters (2018) Vol. 418, pp. 167-175
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
Minghai Zhang, Shanshan Cheng, Yue Jin, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1875, Iss. 2, pp. 188503-188503
Closed Access | Times Cited: 253
Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion
Cheng‐Cao Sun, Youqiong Ye, Zhi Tan, et al.
Science Advances (2023) Vol. 9, Iss. 5
Open Access | Times Cited: 33
MUC1 and MUC16: critical for immune modulation in cancer therapeutics
Xinyi Chen, Ineza Karambizi Sandrine, Mu Yang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model
Rong Wang, Wenli Feng, Hao Wang, et al.
Cancer Letters (2019) Vol. 469, pp. 151-161
Closed Access | Times Cited: 66
Mucins in pancreatic cancer: A well‐established but promising family for diagnosis, prognosis and therapy
Shunda Wang, Lei You, Menghua Dai, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 18, pp. 10279-10289
Open Access | Times Cited: 65
KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer
Cheng He, Kun Fan, Guopei Luo, et al.
Cancer Letters (2019) Vol. 446, pp. 103-111
Closed Access | Times Cited: 64
Multifactorial expression of IL‑6 with update on COVID‑19 and the therapeutic strategies of its blockade (Review)
Elena Niculeț, Valentin Chioncel, Alina Mihaela Elisei, et al.
Experimental and Therapeutic Medicine (2021) Vol. 21, Iss. 3
Open Access | Times Cited: 54
Lewis antigen‑negative pancreatic cancer: An aggressive subgroup
Chen Liu, Shengming Deng, Kaizhou Jin, et al.
International Journal of Oncology (2020)
Open Access | Times Cited: 52
MUC16: clinical targets with great potential
Xin-Yu Zhang, Lian‐Lian Hong, Zhi‐Qiang Ling
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Inhibition of STAT3Y705 phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells
Hangcheng Guo, Yanyi Xiao, Ziwei Yuan, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 25
MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway
Guofeng Zhang, Zheng Ge, Haipeng Zhang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110091-110091
Closed Access | Times Cited: 14
ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
Yuanyuan Lei, Ruochuan Zang, Zhiliang Lu, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 10
Open Access | Times Cited: 37
Update value and clinical application of MUC16 (cancer antigen 125)
Yaan Song, Ming Yuan, Guoyun Wang
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 8, pp. 745-756
Open Access | Times Cited: 11
The function and potential drug targets of tumour-associated Tregs for cancer immunotherapy
Shanshan Yan, Yaguang Zhang, Bing Sun
Science China Life Sciences (2019) Vol. 62, Iss. 2, pp. 179-186
Closed Access | Times Cited: 35
MUC16 mutations improve patients’ prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment
Jing Hu, Jing Sun
OncoImmunology (2018) Vol. 7, Iss. 10, pp. e1487914-e1487914
Open Access | Times Cited: 33
Immunotherapy in pancreatic cancer: New hope or mission impossible?
Jiahong Jiang, Huaixiang Zhou, Chao Ni, et al.
Cancer Letters (2019) Vol. 445, pp. 57-64
Closed Access | Times Cited: 32
Inflammation, microbiota, and pancreatic cancer
Xiaoliang Chen, F.W. Sun, Xuqin Wang, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors
Ping Huang, Minglun Zhao, Jiliang Xia, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
MUC16 C-terminal binding with ALDOC disrupts the ability of ALDOC to sense glucose and promotes gallbladder carcinoma growth
Kun Fan, Jiwen Wang, Wentao Sun, et al.
Experimental Cell Research (2020) Vol. 394, Iss. 1, pp. 112118-112118
Open Access | Times Cited: 25
Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms
Qihang Yuan, Jie Ren, Zhizhou Wang, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 23
The Antimicrobial Effects of Bacterial Cellulose Produced by Komagataeibacter intermedius in Promoting Wound Healing in Diabetic Mice
Chou‐Yi Hsu, Sheng-Che Lin, Yi‐Hsuan Wu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5456-5456
Open Access | Times Cited: 15
2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling
Yangyang Yue, Weikun Qian, Jie Li, et al.
Cancer Letters (2019) Vol. 471, pp. 135-146
Open Access | Times Cited: 24
Killing the “BAD”: Challenges for immunotherapy in pancreatic cancer
Tianjiao Li, Wenquan Wang, Xianjun Yu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 1, pp. 188384-188384
Open Access | Times Cited: 23
P-STAT3 and IL-17 in tumor tissues enhances the prognostic value of CEA and CA125 in patients with lung adenocarcinoma
Xiaoke Chen, Chuanlong Gu, Junqiang Fan, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 125, pp. 109871-109871
Open Access | Times Cited: 21
High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
Qinghua Wang, Yichen Yang, Meng Yang, et al.
Aging (2020) Vol. 12, Iss. 11, pp. 10827-10843
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top